## Special Issue

## Pharmacogenetics and Pharmacogenomics in Personalized Medicine

## Message from the Guest Editor

Pharmacogenomics has made numerous contributions to understanding the variability and explaining the uncertainty of drug responses, and is recognized as a cornerstone of personalized medicine in the future. The aim and scope of the Special Issue is to discover and present genetic variants, biomarkers, and research tools that can be helpful in understanding drug side effects, drug resistance, and human susceptibility to diseases. Cutting-edge research in pharmacogenomics involves studying "the interaction network" after integrating various information obtained from functional genomics. proteomics, transcriptomics, metabolomics, and medical informatics. Moreover, research is focused on creating a standard guideline that can be personalized and applied to humans. Suitable topics for this Special Issue include: pharmacogenomics with human diseases or drugs, such as cardiovascular diseases; psychiatry diseases; gastrointestinal diseases; cancers; drug addictions; drug sensitivities; drug resistances; and adverse drug reactions. We welcome original research papers, reviews, and updated overviews in pharmacogenetics and pharmacogenomics.

## **Guest Editor**

Dr. Su-Jun Lee

Department of Pharmacology and Pharmacogenomics Research Center, College of Medicine, Inje University, Busan, Republic of Korea

### Deadline for manuscript submissions

closed (5 August 2023)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/147575

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

